Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMolina Lamzede Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentMolina HealthcarePolicy C25436-A

    Alpha-Mannosidosis (AM): Lamzede (velmanase alfa-tycv) Coverage Criteria

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C25436-A alerts

    Get alerted when Policy C25436-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and coverage criteria for intravenous Lamzede in adult and pediatric members with alpha-mannosidosis and non-central nervous system manifestations.

    Policy Summary
    PayerMolina Healthcare
    PolicyAlpha-Mannosidosis (AM): Lamzede Coverage Criteria
    Policy CodePolicy C25436-A
    Change TypeNo material change
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionSubmit prior authorization with all initial therapy criteria and qualified prescriber documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 mg/kgLamzede dose
    12 monthsAuthorization duration
    NoneAge restriction
    <10%Deficiency threshold
    Non-CNS

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Approved use

    Coverage Criteria

    Initial Therapy

    Initial therapy is covered when ALL of the following are met.

    Initial therapy criteria

    • Documented diagnosis: Diagnosis of alpha-mannosidosis is documented.
    • Confirmed enzyme or genetic deficiency: Diagnosis is confirmed by deficiency of alpha-mannosidase enzyme activity measured in peripheral blood leukocytes or fibroblasts, with activity less than 10% of a control sample, OR by genetic testing of the MAN2B1 gene.<10% of control sample when enzyme activity is used

      Documentation required.

    • Individualized therapeutic goals: Therapeutic goals are documented based on individual non-neurologic baseline symptoms, including motor function, serum oligosaccharide levels, pulmonary function, overall health, and quality of life.

      Examples include the 3-minute stair climb test, 6-minute walk test, and FVC.

    • Permitted treatment purpose: Lamzede is not being used to treat neurologic manifestations, if present.

      Lamzede does not cross the blood-brain barrier.

    • Transplant history: Member does not have a history of hematopoietic stem cell transplant or bone marrow transplant.
    • Qualified prescriber: Drug is prescribed by or in consultation with a board-certified geneticist, metabolic specialist, endocrinologist, or physician experienced in alpha-mannosidosis or enzyme deficiency disorders.

      Consultation notes must be submitted when applicable.

    Continuation Therapy

    Continuation of therapy is covered when ALL of the following are met.

    Continuation therapy criteria

    • Safety and tolerability: Prescriber attests to, or clinical reviewer finds, no evidence of intolerable adverse effects or drug toxicity, including severe hypersensitivity reactions such as anaphylaxis.
    • Positive clinical response: Documentation demonstrates positive clinical response through low disease activity and/or improvement in signs and symptoms.

      Examples include improved motor function, pulmonary function, reduced infection frequency, or reduced oligosaccharide levels; motor function measures may include the 3-minute stair climb test or 6-minute walk test, and pulmonary function may include FVC.

    Coverage excludes Lamzede use for neurologic or central nervous system manifestations, use in members with a history of hematopoietic stem cell transplant or bone marrow transplant, and other uses outside the labeled non-central nervous system indication. Other uses are considered experimental or investigational and are subject to Molina’s Off-Label policy.

    Coding and Administration Details

    HCPCS CODEHCPCS
    J0217Injection, velmanase alfa-tycy, 1 mg
    Alpha-mannosidase enzyme activity
    Diagnostic thresholdLess than 10% of a control sample
    Infusion duration for members weighing less than 50 kg
    Minimum infusion durationAdminister the total volume over a minimum of 60 minutes
    Maximum infusion rate for members weighing 50 kg or more
    Maximum infusion rate25 mL/hour

    Authorization and Documentation Requirements

    Prior Authorization

    Obtain initial prior authorization

    Prior authorization is required for Lamzede (velmanase alfa-tycv). Initial authorization is for 12 months and requires all initial therapy criteria, including qualified prescriber documentation.

    • Submit documentation supporting the diagnosis, qualifying enzyme or genetic confirmation, individualized non-neurologic therapeutic goals, permitted treatment purpose, and transplant history.
    • Include consultation notes when the drug is prescribed in consultation with a qualified specialist.
    Prior Authorization

    Support 12-month reauthorization

    Reauthorization is granted for 12 months when continuation requirements are met. Submit documentation showing no intolerable adverse effects or drug toxicity and a positive clinical response with low disease activity or improvement in signs and symptoms.

    • Address severe hypersensitivity reactions, including anaphylaxis, if applicable.
    • Document objective or clinical improvement, such as improved motor or pulmonary function, reduced infection frequency, or reduced oligosaccharide levels.

    Clinical Background

    Alpha-mannosidosis is a rare autosomal recessive lysosomal storage disorder caused by mutations in the MAN2B1 gene and deficiency of the alpha-mannosidase enzyme. Accumulation of mannose-rich oligosaccharides may lead to recurrent infections, hepatosplenomegaly, hearing impairment, muscular weakness, joint abnormalities, ataxia, and other systemic manifestations. Lamzede provides exogenous alpha-mannosidase but does not cross the blood-brain barrier and is not expected to treat central nervous system manifestations.

    Key Definitions

    Alpha-mannosidase deficiency
    DefinitionAlpha-mannosidase activity of less than 10% of a control sample in peripheral blood leukocytes or fibroblasts demonstrates enzyme deficiency.
    Non-central nervous system manifestations
    DefinitionManifestations of alpha-mannosidosis outside the central nervous system; Lamzede is indicated for these manifestations in adult and pediatric patients.

    Lamzede Initial Therapy

    Lamzede Initial Therapy

    Initial therapy requires ALL of the following clinical and documentation criteria.

    Lamzede initial therapy

    • Documented diagnosis: Diagnosis of alpha-mannosidosis is documented.
    • Diagnostic confirmation: Diagnosis is confirmed by deficiency of alpha-mannosidase enzyme activity measured in peripheral blood leukocytes or fibroblasts, with activity less than 10% of a control sample, OR by genetic testing of the MAN2B1 gene.<10% of control sample when enzyme testing is used

      Documentation required.

    • Therapeutic goals: Individualized therapeutic goals are documented based on non-neurologic baseline symptoms, including motor function, serum oligosaccharide levels, pulmonary function, overall health, and quality of life.

    Lamzede Continuation

    Lamzede Continuation

    Continuation therapy requires ALL of the following.

    Lamzede continuation

    • Safety and tolerability: Prescriber attests to, or clinical reviewer has found, no evidence of intolerable adverse effects or drug toxicity, including severe hypersensitivity reactions such as anaphylaxis.
    • Positive clinical response: Documentation demonstrates a positive clinical response through low disease activity and/or improvement in the condition's signs and symptoms.

      Clinical response may include improved motor function, improved pulmonary function, reduced frequency of infections, or reduced oligosaccharide levels. Motor function measures may include the 3-minute stair climb test or 6-minute walk test, and pulmonary function may include FVC.

    Dose and Quantity Limits

    Lamzede (velmanase alfa-tycv)
    Dose quantity limit1 mg/kg based on actual body weight, once weekly

    Infusion Site of Care

    Billing Rule

    Administer in a recommended infusion-center setting

    Lamzede infusions are recommended for pharmacy or medical benefit coverage in a non-inpatient hospital facility-based location under Molina’s Site of Care program.

    • Use a facility-based, non-inpatient hospital location such as an infusion center.
    • The Site of Care Utilization Management Policy applies.
    Policy Summary
    PayerMolina Healthcare
    PolicyAlpha-Mannosidosis (AM): Lamzede Coverage Criteria
    Policy CodePolicy C25436-A
    Change TypeNo material change
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionSubmit prior authorization with all initial therapy criteria and qualified prescriber documentation.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Administration DetailsAuthorization and Documentation RequirementsClinical BackgroundKey DefinitionsLamzede Initial TherapyLamzede ContinuationDose and Quantity LimitsInfusion Site of Care
    Documentation Required

    Submit complete medical-necessity documentation

    Submit complete medical rationale with the request. Molina may also require patient records, test results, and credentials of the provider ordering or performing the drug or service.

    • Provide additional documentation when requested for coverage determination, quality improvement, or fraud, waste, and abuse review.
    • Documentation must support medical necessity and that the treatment is not investigational or experimental.
    Documentation Required

    Confirm alpha-mannosidosis diagnosis

    Document the diagnosis of alpha-mannosidosis and confirm it by alpha-mannosidase enzyme activity measured in peripheral blood leukocytes or fibroblasts, or by genetic testing of the MAN2B1 gene.

    • When enzyme testing is used, activity must be less than 10% of a control sample.
    • Diagnostic confirmation is required.
    Documentation Required

    Document baseline therapeutic goals

    Document individualized therapeutic goals based on the member’s baseline non-neurologic symptoms and clinical status.

    • Address motor function or stabilization, such as the 3-minute stair climb test or 6-minute walk test.
    • Include relevant serum oligosaccharide levels, pulmonary function such as FVC, overall health, and quality of life.
    Documentation Required

    Confirm permitted use and transplant history

    Document that Lamzede is not being used to treat neurologic manifestations, if present, and that the member has no history of hematopoietic stem cell transplant or bone marrow transplant.

    • Confirm the absence of prior HSCT or bone marrow transplant.
    • Limit the requested treatment purpose to non-neurologic manifestations.
    Documentation Required

    Document response for continuation

    For continuation requests, document no intolerable adverse effects or drug toxicity and a positive clinical response demonstrated by low disease activity and/or improvement in signs and symptoms.

    • Address severe hypersensitivity reactions, including anaphylaxis.
    • Report relevant response measures, including motor or pulmonary function, infection frequency, or oligosaccharide levels.
    Prior Authorization

    Use a qualified prescriber or consultant

    Lamzede must be prescribed by or in consultation with a board-certified geneticist, metabolic specialist, endocrinologist, or physician experienced in managing alpha-mannosidosis or enzyme deficiency disorders.

    • If prescribed in consultation, submit consultation notes with the initial request and reauthorization requests.
    Denial Risk

    Avoid noncovered uses and transplant-history conflicts

    Coverage may be denied when Lamzede is used to treat neurologic or central nervous system manifestations, when the member has a history of hematopoietic stem cell transplant or bone marrow transplant, or when the requested use is outside the labeled non-central nervous system indication.

    • Document that the treatment is for permitted non-neurologic manifestations.
    • Confirm no history of HSCT or bone marrow transplant.
    Denial Risk

    Prevent documentation-related denial

    Coverage may be denied when the diagnosis is not documented, alpha-mannosidase deficiency or MAN2B1 genetic confirmation is not established, therapeutic goals are not submitted, or required clinical documentation does not support medical necessity.

    • Provide enzyme activity results or MAN2B1 genetic testing when applicable.
    • Submit individualized therapeutic goals and complete supporting medical records, test results, and provider credentials when requested.
    Denial Risk

    Do not use for experimental or investigational indications

    All other uses of Lamzede are considered experimental or investigational and are subject to Molina’s Off-Label policy.

    • Do not request coverage for uses outside the labeled indication and policy criteria without addressing the applicable Off-Label policy.
    Denial Risk

    Meet continuation safety and response criteria

    Continuation may be denied when there is evidence of intolerable adverse effects or drug toxicity, including severe hypersensitivity reactions such as anaphylaxis, or when there is no documented positive clinical response.

    • Document low disease activity and/or improvement in signs and symptoms for continuation.
    • If a severe hypersensitivity reaction occurs, discontinue Lamzede immediately and initiate appropriate medical treatment.

    Examples include the 3-minute stair climb test, 6-minute walk test, and FVC.

  1. Non-neurologic treatment purpose: Documentation confirms that Lamzede is not being used to treat neurologic manifestations, if present.

    Lamzede does not cross the blood-brain barrier.

  2. Transplant history: Documentation confirms that the member does not have a history of hematopoietic stem cell transplant or bone marrow transplant.
  3. Qualified prescriber or consultant: Lamzede is prescribed by or in consultation with a board-certified geneticist, metabolic specialist, endocrinologist, or physician experienced in the management of alpha-mannosidosis or enzyme deficiency disorders.

    If prescribed in consultation, consultation notes must be submitted with the initial request.